High expression of LGR6 is a poor prognostic factor in esophageal carcinoma
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p><jats:bold>Background:</jats:bold> Leucine-rich repeat-containing G-protein-coupled receptor 6 (LGR6) promotes carcinogenesis and progression in some cancer types. However, there are few reports of <jats:italic>LGR6</jats:italic> expression in esophageal squamous cell carcinoma (ESCC). <jats:italic>LGR6</jats:italic> expression and clinicopathological features in ESCC were investigated by RNAscope, a high-sensitivity RNA <jats:italic>in situ</jats:italic> hybridization method.<jats:bold>Methods: </jats:bold>Appropriate tumors were selected from 41 cases of ESCC from which tissue microarrays were generated, and <jats:italic>LGR6</jats:italic> expression was identified by RNAscope. <jats:bold>Results:</jats:bold> Thirty-seven patients had <jats:italic>LGR6</jats:italic> expression. High <jats:italic>LGR6</jats:italic> expression was observed in 17 cases and low <jats:italic>LGR6</jats:italic> expression in 24 cases. <jats:italic>LGR6</jats:italic> expression was significantly higher in high histological grade ESCC than in low histological grade ESCC (<jats:italic>P</jats:italic>=0.0023). ESCC patients who received neoadjuvant chemotherapy had significantly higher <jats:italic>LGR6 </jats:italic>expression than those without neoadjuvant chemotherapy (<jats:italic>P</jats:italic>=0.0109). Furthermore, high <jats:italic>LGR6 </jats:italic>expression showed a poorer prognosis than low <jats:italic>LGR6 </jats:italic>expression (log-rank test, <jats:italic>P</jats:italic>=0.0365).<jats:bold>Conclusions: </jats:bold><jats:italic>LGR6 </jats:italic>may be a prognostic factor and a potential new therapeutic target in ESCC.</jats:p>
収録刊行物
-
- Pathology - Research and Practice
-
Pathology - Research and Practice 242 154312-, 2023-02
Elsevier BV